Is Altamira Therapeutics Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Altamira Therapeutics Ltd (CYTOF) is currently classified as NOT HALAL as of September 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Altamira Therapeutics Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Altamira Therapeutics Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Altamira Therapeutics Ltd?

Muslim investors may consider investing in Altamira Therapeutics Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Altamira Therapeutics Ltd classified as NOT HALAL?

Musaffa determines the Shariah status of Altamira Therapeutics Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Altamira Therapeutics Ltd updated?

The Shariah compliance status of Altamira Therapeutics Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Altamira Therapeutics Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Altamira Therapeutics Ltd?

You can check the latest Shariah compliance status of Altamira Therapeutics Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

CYTOF Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: September 19, 2025

Report Source: 2025 2nd Quarter Report

Altamira Therapeutics Ltd. Stock Analysis CYTOF

United States Health Care Nano Cap Report: Q2, 2025

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. The company employs 13 full-time employees The company went IPO on 2014-08-06. The firm has over two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. Its delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down. AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. AM-401, the drug product is based on its OligoPhore technology.

Key Statistics of Altamira Therapeutics Ltd (CYTOF)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.08$0.08

Today's Open

$0.08

Volume

124.00

P/E Ratio (TTM)

52 Week Range

$0.05$0.15

Market Cap

604.01K

Avg. Volume

5770.53

Dividend Yield

Financial Metrics & Statements of Altamira Therapeutics Ltd (CYTOF)

FAQ's for Altamira Therapeutics Ltd (CYTOF)

According to Musaffa’s Shariah screening methodology, Altamira Therapeutics Ltd (CYTOF) is currently classified as NOT HALAL as of September 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.